Bayesian Designs for Phase I-II Clinical Trials (Chapman & Hall/CRC Biostatistics Series)

Yuan, Ying; Nguyen, Hoang Q.; Thall, Peter F.

ISBN 10: 1032242647 / ISBN 13: 9781032242644

Edité par Chapman and Hall/CRC (edition 1), 2021

A propos de cet article

It's a preowned item in good condition and includes all the pages. It may have some general signs of wear and tear, such as markings, highlighting, slight damage to the cover, minimal wear to the binding, etc., but they will not affect the overall reading experience.

N° de réf. du vendeur 1032242647-11-1

Détails bibliographiques

• Titre: Bayesian Designs for Phase I-II Clinical Trials (Chapman & Hall/CRC Biostatistics Series)
• Éditeur: Chapman and Hall/CRC (edition 1)
• Date de parution: 2021
• Langue: anglais
• ISBN à 10 chiffres: 1032242647
• ISBN à 13 chiffres: 9781032242644
• Reliure: Paperback
• Édition: 1.
• État de l'article: Good

A propos de ce titre

Synopsis

Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources.

Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.

Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.

À propos de l?auteur

Ying Yuan is a professor and co-chief of the Section of Adaptive Clinical Trials in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct associate professor in the Department of Statistics at Rice University. Dr. Yuan has published over 100 peer-reviewed research papers in top statistical and medical journals. He is an associate editor of Biometrics and a board member of the International Chinese Statistical Association. He received his PhD in biostatistics from the University of Michigan. His research interests include Bayesian adaptive clinical trial design, statistical analysis of missing data, and Bayesian statistics.

Hoang Q. Nguyen is a senior computational scientist in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He received his PhD in computational and applied mathematics from Rice University. His research interests include Bayesian clinical trial design, computational algorithms, regression modeling, and Bayesian data analysis.

Peter F. Thall is the Anise J. Sorrell Professor in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct professor in the Department of Statistics at Rice University. Dr. Thall is a fellow of the American Statistical Association (ASA) and the Society for Clinical Trials, an associate editor for Clinical Trials and Statistics in Biosciences, and an ASA Media Expert. He has published over 200 papers and book chapters in the statistical and medical literature. He received his PhD in statistics and probability from the Florida State University. His research interests include clinical trial design, dynamic treatment regimes, prior elicitation, Bayesian nonparametric statistics, and personalized medicine.